UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Oligodendroglioma
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant glioma.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase 1/2a study to assess the safety, dose-limiting toxicities, recommended Phase 2 schedule, and preliminary efficacy of aminolevulinic acid sonodynamic therapy in patients with recurrent or progressive GBM.
Conditions
Glioblastoma (grade IV)
Glioma
This is a multicenter phase III clinical trial comparing the combination of an implanted focused ultrasound device and carboplatin chemotherapy versus the standard-of-care second line chemotherapy with either lomustine or temozolomide.
Conditions
Glioblastoma (grade IV)
Glioma
This is an open-label phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of the drug TNG908 in patients with MTAP-deleted advanced or metastatic solid tumors.
Conditions
Glioma
Glioblastoma (grade IV)
The purpose of this prospective, self-controlled study is to evaluate the safety and
effectiveness of using focused ultrasound in adults with glioblastoma to increase temporarily the permeability of the blood-brain barrier, allowing increased passage of circulating free DNA for sampling and analysis.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase II clinical trial will evaluate the efficacy of dabrafenib and trametinib after radiation therapy in children and young adults with BRAF V600 mutant high-grade glioma.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Summary
This phase II clinical trial will evaluate the efficacy and side effects of larotrectinib in treating patients with previously untreated TRK fusion solid tumors (including central nervous system (CNS) tumors) and relapsed TRK fusion acute leukemia.
Conditions
Glioma
Glioblastoma (grade IV)
This is a phase I/II trial that aims to to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the blood-brain barrier increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.
Conditions
Glioblastoma (grade IV)
Summary
This is a prospective, randomized, placebo-controlled, multi-center study of patients with newly diagnosed glioblastoma to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (Arm A) versus